The opening of the World Lung Cancer Congress is Professor Wu Yilong: Lung cancer slow disease and long survival is not far away

Recently, the 21st World Lung Cancer Congress, organized by the International Lung Cancer Research Association and to be held online in the form of a global virtual conference, took the lead in disclosing the research summary on the official website, when 11 OA (oral reports) will be set up to publish a number of heavy lung cancer research data.
statistics, the number of new cases of lung cancer in China in 2020 is about 816,000, an average of 3 patients diagnosed with lung cancer every two minutes! The situation of lung cancer prevention and treatment is still serious, and people pay more attention to and look forward to the new breakthrough in lung cancer treatment.
But the reason why the World Lung Cancer Congress has attracted the attention of the industry and the public is that the President of the Conference is a leading figure in the field of lung cancer in China - Professor Wu Yilong, LifeLong Director of Guangdong Provincial People's Hospital and Honorary Director of Guangdong Lung Cancer Research Institute, who is also the first Chinese doctor to serve as President of the World Lung Cancer Congress! Immunotherapy allows patients with advanced lung cancer to survive for a long time, and advanced lung cancer is considered to be a "terminal illness" that is unlikely to last 5 to 10 years.
past lung cancer data also show that patients with advanced lung cancer have a five-year survival rate of only about 5 percent -- that is, more than 90 out of 100 patients are more than five years old.
recently, Professor Wu Yilong said in an interview that advanced lung cancer is shifting to chronic disease and long-term survival.
if a disease has a long course of disease, can be treated, can also be prevented and controlled, the disease can be considered a chronic disease.
recent years, the survival and quality of life of patients with advanced lung cancer have improved significantly, thanks to advances in treatment methods, particularly with the approval of innovative therapies such as targeted and immunotherapy.
Wu Yilong stressed: "We now want to turn advanced lung cancer into a chronic disease!" Professor Wu Yilong believes that the development of advanced lung cancer treatment has experienced two watersheds in the past few decades.
the first time, around 2013, targeted drugs benefited patients with advanced lung cancer who had targets for drive gene mutations, and again, after 2015, immunotherapy used to benefit patients who did not drive targets for gene mutations.
And immunotherapy is different from the traditional treatment mechanism, its biggest feature is not to kill cancer cells directly, but let immune cells find tumor cells to destroy it, and immunotherapy after the effect of some patients can be long-term maintenance, bringing long-term survival benefits.
he referred to a clinical study code-named KEYNOTE-024, which aimed to assess the effectiveness and safety of the platinum-containing chemotherapy treatment PD-L1 TPS≥50%, advanced NSCLC primary treatment patients without EGFR and ALK-driven gene mutations selected by the Pabli pearl mono-contrast researchers, and to be available to the European Society of Oncology in 2020 (European Society of Oncology) ESMO)'s annual meeting for the first time published its five-year survival data: Pabli pearl single resistance group patients with a five-year survival rate of 31.9%, in addition, in patients who received a complete 2 years or more of drug use, the five-year survival rate of the use of Pabliju single drug is as high as 81.4%, of which 46% of patients have completely stopped treatment, to the patients with advanced lung cancer has brought great encouragement.
1.png KEYNOTE-024 Study: Five-year OS data standardized immunotherapy can maximize the benefits of patients At present, a number of immunotherapy drugs, including PD-1 inhibitors and PD-L1 inhibitors, have been listed in China, patients also benefit from its long-term survival of the efficacy of "the rush."
, the popularity and standardized use of immunotherapy drugs are also problems clinicians are facing.
As the head of the anti-tumor drug professional group of the National Health Care Commission's Committee of Experts on Rational Drug Use, Professor Wu Yilong participated in the preparation of the Guidelines for the Clinical Application of New Anti-Tumor Drugs (2020 Edition), issued by the National Health and Wellness Commission on December 29, 2020, which further standardizes the clinical application of new anti-tumor drugs and gives doctors more normative guidance.
Professor Wu Yilong suggested that although immunotherapy has a broad spectrum, but each immunotherapy drug is approved on the basis of independent clinical trial data, doctors should strictly abide by the drug approval of the certificate of adaptation, comprehensive consideration of the patient's physical condition and clinical data of the drug and other conditions of re-use.
if different drugs are approved with the same certificate of adaptation, the doctor will be based on the patient's situation, combined with the effectiveness of the drug, safety, and other factors to develop a treatment plan.
so lung cancer doctors need to be very familiar with the drug and evidence data to help patients maximize survival benefits, so that every patient can enjoy standardized quality treatment.
, Professor Wu Yilong, together with his team of experts, has brought us a CTONG scoring system, which is more in line with China's national conditions.
CTONG scoring system combines effectiveness, safety, quality of life and compensation with clinical effects and gives them different weights.
, effectiveness is the most critical part of the CTONG score, including progress-free survival (PFS) and total lifetime (OS) of treatment, with OS as the primary basis for judgment.
2.jpg Through the guidance of CTONG scoring system, the treatment plan given by the doctor is a comprehensive judgment combining effectiveness, safety, patient quality of life and compensation, which may not be the best treatment effect, but it is the most suitable for patients at this stage.
The future of immunotherapy and the broader future of lung cancer treatment is to be able to detect lung cancer early in a simpler way, and to treat patients with more precise and even "tailored" treatment options, said Professor Wu Yilong.
Based on the experience of the Guangdong Provincial People's Hospital in opening an immunization clinic for one year, immune clinics can indeed help patients detect serious adverse reactions earlier and deal with them in a timely manner, avoiding the possibility of about 30% developing into irreversible conditions, reducing the proportion of patients hospitalized and better encouraging patients to return to their families and society.
same time, clinical trials related to global immunotherapy are in the hot water, doctors are still exploring more ways to improve the efficiency of treatment, and many Chinese researchers and Chinese research data will appear at the 21st World Lung Cancer Congress.
development of cutting-edge medical methods will certainly enable the level of lung cancer treatment to be raised again, benefit more patients with lung cancer and even other cancers, and help build a healthy China.
source: Medical Valley.com Copyright Notice: All text, images and audio and video materials that indicate "Source: Mets Medicine" or "Source: MedSci Originals" on this website are owned by Mets Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here